Follow us on:
Learn, discover & invest in smallcases across different types to build your long term portfolio.
Explore from India`s leading investment managers and advisors curating their strategies as smallcases.
Diversify your portfolio by investing in Global brands.
Pre-configured baskets of stocks & ETFs that you can invest in with a single click. Developed by hedge funds, global asset management companies, experienced wealth management firms and portfolio managers.
Fundamental, Stock Ideas, Multibaggers & Insights
Stock & Index F&O Trading Calls & Market Analysis
Technical Call, Trading Calls & Insights
Commodity Trading Calls & Market Analysis
Currency Derivatives Trading Calls & Insights
Options Trading Advice and Market Analysis
MARKET SMITH INDIA
Model portfolios, Investment Ideas, Guru Screens and Much More
Proprietary system driven Rule Based Trading calls
Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas
STOCK REPORTS BY THOMSON REUTERS
Details stock report and investment recommendation
POWER YOUR TRADE
Technical and Commodity Calls
Set price, volume and news alerts
STOCKAXIS EMERGING MARKET LEADERS
15-20 High Growth Stocks primed for price jumps
BSE: 542841 | NSE: |
ISIN: INF204KB14G6 | SECTOR: MiscellaneousMiscellaneous
Bid Price (Qty.)
Offer Price (Qty.)
Buy HDFC Standard Life Insurance; target of Rs 518: Prabhudas Lilladher
Buy MCX; target of Rs 1302: Axis Direct
Neptune Exports' board meeting on April 28, 2017
Kaya's board meeting on May 03, 2017
BSE Q3 net profit drops 17% to Rs 64 cr
Thomas Cook India Group swings to profit
Cox & Kings Q3 net down 85% at Rs 15 cr
Adani Transmission Q3 net profit up 33% at Rs 99.28 cr
Titan Q3 net seen flat at Rs 225 cr, jewellery biz may grow 10%
Just Dial Q3 profit seen down 5% on weak operational performance
VGuard Q3 PAT may dip 36.8% to Rs 20 cr: HDFC Securities
Jubilant Food Q3 PAT seen up 10.4% to Rs 20 cr: HDFC Securities
High pizza cost tricky? Analysts like Jubilant Food post poor Q1
Strong pipeline, Europe profits, US to drive Aurobindo growth
A tale of 2 pharma companies: Aurobindo shines, Sun Coughs
Bull vs Bear: What's the outlook on Sun Pharma?
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.